DeepQure's Novel Extravascular RDN Device Shows Promise in Global Hypertension Trials
• DeepQure's innovative HyperQure™ device demonstrates successful blood pressure reduction in initial trials across South Korea and the United States, with no reported complications.
• The company is expanding clinical trials to six leading U.S. universities, including Mayo Clinic and Stanford, aiming to enroll 15 patients in H1 2025 before initiating a pivotal study.
• DeepQure is broadening its technology application to treat atrial fibrillation, potentially offering an improved solution to reduce the 30-50% recurrence rates seen with current PVI treatments.
© Copyright 2025. All Rights Reserved by MedPath